GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

NCT00480025 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2278

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.

Conditions

Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL: GSK1572932A Antigen-Specific Cancer Immunotherapeutic
BIOLOGICAL: Placebo Control

Sponsor

GlaxoSmithKline